摘要
目的探讨地奥司明对老年慢性前列腺炎患者血清及前列腺液免疫介导因子的影响及临床疗效研究。方法选取已确诊为慢性非细菌性前列腺炎的老年男性患者89例,采用随机数字表将患者随机分为实验组和对照组,对照组44例,予普适泰片治疗,实验组45例,在对照组基础上予以地奥司明治疗,疗程12周。观察2组老年慢性前列腺炎患者血清及前列腺液MIP-2、MIP-1α含量、临床疗效及不良反应。结果与对照组比较,实验组血清、前列腺液中MIP-1α、MIP-2含量较低(P<0.05),NIH-CPSI评分及QOL评分较低(P<0.05),总有效率高于对照组(P<0.05),不良反应明显低于对照组(P<0.05)。结论地奥司明治疗慢性非细菌性前列腺炎能够降低患者血清、前列腺液中MIP-1α、MIP-2含量,改善盆腔疼痛、排尿困难、性功能障碍等症状,且不良反应小。
Objective To explore effect of diosmin on serum and prostatic fluid immune mediated factors and clinical effect in patients with chronic prostatitis.Methods 89 cases of old male patients with chronic non bacterial prostatitis were selected, and divided into two groups.The control group were treated with universal tablets, the experiment group were treated on the base of the control group with diosmin.12 weeks as a course.Clinic effect, adverse reaction rate, prostatic fluid MIP-2 and MIP-1αwere compared after treatment.Results Compared with control group, MIP-1αand MIP-2 in serum and prostatic fluid were lower（P〈0.05）,NIH-CPSI score and QOL scores were lower（P〈0.05）, total effective rate was higher than control group（P〈0.05）,the incidence of adverse reactions was lower（P〈0.05）.Conclusion Diosmin can reduce MIP-1α, MIP-2 in serum and prostate fluid of patients with chronic none bacterial prostatitis, and improve the pelvic pain, dysuria, sexual dysfunction and other symptoms, and has less adverse reaction.
出处
《中国生化药物杂志》
CAS
2015年第6期121-123,126,共4页
Chinese Journal of Biochemical Pharmaceutics
